Key result
Long-term beta-blocker use was associated with reduced rates of late cardiac death or myocardial infarction after major vascular surgery, except in patients with ≥3 risk factors and positive DSE.
Why the study?
Does long-term beta-blocker therapy reduce late cardiac death or myocardial infarction in patients who survived major vascular surgery?
Cohort (n=1,286)
Does long-term beta-blocker therapy reduce late cardiac death or myocardial infarction in patients who survived major vascular surgery?
Long-term beta-blocker therapy is associated with a reduction in late cardiac events after major vascular surgery, except in patients with 3 or more risk factors and positive dobutamine stress echocardiography.
May support selective long-term beta-blockers after vascular surgery; hypothesis-generating and requires randomized confirmation.
BACKGROUND: Survivors of major vascular surgery are at increased risk of late cardiac complications. OBJECTIVE: To examine the cardioprotective effect of beta-blockers. METHODS: A follow-up study was conducted in 1286 patients who survived surgery for at least 30 days. Patients were screened for cardiac risk factors and dobutamine stress echocardiography (DSE) results; 1034 patients (80%) underwent preoperative DSE, and 370 (29%) received beta-blockers. The main outcome measure was late cardiac death or myocardial infarction. RESULTS: Seventy-four patients (5.8%) had late cardiac events. Cardiac event rates in patients with 0, 1 to 2, and 3 or more risk factors were 1.6%, 4.7%, and 19.2%, respectively. In patients without risk factors, beta-blockers were associated with improved event-free survival (2.8% vs 0%), and DSE had no additional prognostic value. In patients with 1 to 2 risk factors, the presence of ischemia during DSE increased cardiac events from 3.9% to 9.8%. However, if patients with ischemia were treated with beta-blockers, the risk decreased to 7.2%. In patients with 3 or more risk factors, DSE and beta-blockers stratified patients into intermediate- and high-risk groups. In patients without ischemia, beta-blockers reduced the cardiac event rate from 15.1% to 9.5%, whereas the cardioprotective effect was limited in patients with 3 or more risk factors and positive DSE findings. CONCLUSIONS: Long-term beta-blocker use is associated with a reduction in the cardiac event rate, except for patients with 3 or more risk factors and positive findings on DSE.
No takes yet. Share an insight, caveat, or question.
Miklós D. Kertai (2003) conducted a cohort in Survivors of major vascular surgery (n=1,286). Beta-blocker therapy vs. No beta-blocker therapy was evaluated on Late cardiac death or myocardial infarction. Long-term beta-blocker use was associated with reduced rates of late cardiac death or myocardial infarction after major vascular surgery, except in patients with ≥3 risk factors and positive DSE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: